BlackRock Health Sciences Opportunities Portfolio

Intrinsiqq's two-stage DCF estimates an intrinsic value of about $186.03 per share for BME, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $139.52. At today's $45.53, that puts the stock about 308.6% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.

BlackRock Health Sciences Opportunities Portfolio scores 49 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a mixed business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.

Yes, BlackRock Health Sciences Opportunities Portfolio pays a regular dividend of about $3.14 per share per year (typically in quarterly installments), a yield of roughly 6.9% at the current price. That is a payout ratio of about 58.8% of earnings, so the dividend is well covered. BlackRock Health Sciences Opportunities Portfolio has grown the dividend at roughly 10.4% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For BME's full payout history, growth streak and dividend-safety score, see the dividends tab.

That depends on valuation and quality together, not either alone. BME currently trades below its estimated intrinsic value and scores 49/100 on quality (mixed). It also yields about 6.9%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.